Immunotherapy has emerged as a breakthrough treatment for cancer.
Several stakes are involved in the development of this revolutionary therapy – clinical, scientific, ethical and regulatory.
The French Society for Cancer Immunotherapy (FITC) was created to unite all the actors involved in the success of immunotherapy within a single body. The FITC represents French expertise at both national and international arenas in this new era of cancer therapy.
Our mission
Facilitate pluri-disciplinary interactions and communication
By developing digital platforms, organizing scientific meetings and training, we bring together scientists, clinicians, patients, ethics committees and regulatory bodies.
Promote medical and scientific research in cancer immunology and immunotherapy
By encouraging collaborative research between scientific and clinical laboratories while facilitating the development of novel diagnostic tests, treatments and therapeutic molecules.
Advance education of patients and their families
A key for the successful implementation of immunotherapy, the FITC is dedicated to developing accessible-for-all tools that will help patients through their treatment notably in understanding and managing side-effects.
Improve access to immunotherapy
Presently in France, access to immunotherapy is a major challenge. The FITC represents clinicians, healthcare workers and scientists working with governing bodies to improve patient access to immunotherapy.
A key strategy being spearheaded by the FITC is to increase visibility of clinical trials open for inclusion and define national recommendations for cancer immunotherapy.
The bureau
Marion ALCANTRA
President
Aurélien MARABELLE
Vice-President
Cédric ROSSI
Secretary
Diane DAMOTTE
Vice-Secretary
Carlos GOMEZ-ROCA
Treasurer
Clélia COUTZAC
Vice-Treasurer
The board of directors
Marion ALCANTARA – Institut Curie, Paris
Stéphane CHAMPIAT – Gustave Roussy, Villejuif
Clélia COUTZAC – Centre Léon Bérard, Lyon
Stéphane DALLE – Hospices Civils de Lyon
Diane DAMOTTE – Institut Cochin, Paris
Stéphane DEPIL – Centre Léon Bérard, Lyon
Emmanuel DONNADIEU – Institut Cochin, Paris
Brigitte DRÉNO – CHU de Nantes
Amélie FEYEUX – CH Bourg-En-Bresse
Carlos GOMEZ-ROCA – IUCT Toulouse
Aurélien MARABELLE – Gustave Roussy, Villejuif
Maurice PÉROL – Centre Léon Bérard, Lyon
Cédric ROSSI – CHU de Dijon-Bourgogne
Magali TERME – Université de Paris, PARCC
With the support of
